Inactivated Seasonal Influenza Vaccines Increase Serum Antibodies to the Neuraminidase of Pandemic Influenza A(H1N1) 2009 Virus in an Age-Dependent Manner

Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
The Journal of Infectious Diseases (Impact Factor: 6). 10/2010; 202(11):1634-8. DOI: 10.1086/657084
Source: PubMed


Levels of preexisting antibodies to the hemagglutinin of pandemic influenza A(H1N1) 2009 (hereafter pandemic H1N1) virus positively correlate with age. The impact of contemporary seasonal influenza vaccines on establishing immunity to other pandemic H1N1 proteins is unknown. We measured serum antibodies to the neuraminidase (NA) of pandemic H1N1 in adults prior to and after vaccination with seasonal trivalent inactivated influenza vaccines. Serum antibodies to pandemic H1N1 NA were observed in all age groups; however, vaccination elevated levels of pandemic H1N1 NA antibodies predominately in elderly individuals (age, ⩾60 years). Therefore, contemporary seasonal vaccines likely contribute to reduction of pandemic H1N1-associated disease in older individuals.

Download full-text


Available from: Nicholas Negovetich,
  • Source
    • "The immunogenicity of different influenza vaccine formulations was studied in the 1970s; despite the fact that whole virus was found to be more immunogenic compared to other formulations, its use was discontinued in most countries and it was replaced with the less reactogenic split or subunit influenza vaccine18192021. Although the latter have been proven to be safe, several studies have demonstrated decreased magnitude and longevity of the immune responses after intramuscular administration especially in high risk groups such as the elderly, immunocompromised individuals and children222324. These facts strongly suggest the necessity for new vaccine formulations or new delivery methods that could improve the immune responses, thus reducing morbidity and mortality from influenza infection worldwide. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Influenza infection represents a major socio-economic burden worldwide. Novel delivery methods can render influenza vaccination easier and more acceptable by the public, and importantly confer protection equal or superior to that induced by conventional systemic administration. An attractive target for vaccine delivery is the skin. Recent studies have demonstrated improved immune responses after transdermal delivery of inactivated influenza virus with microneedle patches. Here we show that immunization with a licensed influenza subunit vaccine coated on metal microneedles can activate both humoral and cellular arms of the immune response and confer improved long-term protection in the mouse model when compared to the conventional systemic route of delivery. These results demonstrate the promising potential of microneedle delivery of licensed influenza subunit vaccines, that could be beneficial in increasing vaccine coverage and protection and reducing influenza-related mortality worldwide.
    Scientific Reports 04/2012; 2:357. DOI:10.1038/srep00357 · 5.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We measured haemagglutination inhibiting (HI) serum antibody titers to vaccine matched A/H1N1 influenza virus strain and to the new pandemic 2009 A/H1N1 (pH1N1) virus in two groups of volunteers prior and after 2003/2004 or 2007/2008 influenza seasonal vaccine administration. The responses were examined considering the overall volunteers studied in the two winters (144 and 79, respectively) and grouping those subjects in birth cohort classes (1903–1919; 1920–1957; 1958–1977). Before vaccination, HI antibody titers were found in all the groups examined and, on comparing the different age-groups, titers were higher in the younger groups as compared with the oldest against the A/H1N1 seasonal strains but titers were higher in the oldest as compared with the younger ones against the pH1N1 strain. Vaccination induced significant increases in HI titers against the matched A/H1N1 vaccine strains in all the groups examined. The responses satisfied the EMEA criteria and were higher in the youngest volunteers as compared with older groups. Increases were also found in the level of cross-reactive HI antibodies to the new pandemic 2009 A/H1N1 virus although in most instances the requirements of the EMEA were not met.
    Procedia in Vaccinology 12/2011; 4:50-58. DOI:10.1016/j.provac.2011.07.008
  • Source

    Clinical Infectious Diseases 03/2011; 52(6):830-831. DOI:10.1093/cid/cir039 · 8.89 Impact Factor
Show more